|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...2021222324252627282930...39313932» |
- | Talvey (talquetamab-tgvs) / J&J
Trial initiation date: Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (clinicaltrials.gov) - Sep 20, 2024
P2, N=30, Not yet recruiting, Sponsor: Stanford University
Initiation date: Jul 2024 --> Nov 2024
- izuralimab (XmAb23104) / Xencor
Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study of XmAb23104 in People With Sarcoma (clinicaltrials.gov) - Sep 20, 2024
P2, N=6, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Jul 2024 --> Nov 2024 Trial completion date: Apr 2025 --> Jul 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2025 --> Jul 2024; Vendor decided study to be closed early
- | huCART19 / Novartis
Trial completion, Trial completion date, Trial primary completion date: Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov) - Sep 20, 2024
P2, N=106, Completed, Sponsor: University of Pennsylvania
Trial completion date: Apr 2025 --> Jul 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2025 --> Jul 2024; Vendor decided study to be closed early Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2024
- || felzartamab (MOR202) / Biogen
P1/2 data, Journal: Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. (Pubmed Central) - Sep 20, 2024
P1/2
Serum albumin increased from baseline to EOS in 20 of 26 patients (76.9%) (C1, 12/15 [80.0%]; C2, 8/11 [72.7%]). In this population with high-risk anti-PLA2R+ PMN, felzartamab was tolerated and resulted in rapid partial and complete immunologic responses and partial improvements in proteinuria and serum albumin in some patients.
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment change, Trial completion date, Trial termination, Metastases: Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy (clinicaltrials.gov) - Sep 20, 2024
P4, N=2, Terminated, Sponsor: M.D. Anderson Cancer Center
In this population with high-risk anti-PLA2R+ PMN, felzartamab was tolerated and resulted in rapid partial and complete immunologic responses and partial improvements in proteinuria and serum albumin in some patients. N=15 --> 2 | Trial completion date: Oct 2026 --> Aug 2024 | Recruiting --> Terminated; PI Request
- | AiTan (rivoceranib) / HLB Bio Group, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P1/2 trial, Metastases: The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=66, Not yet recruiting, Sponsor: Xianglin Yuan
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion, Metastases: MIMIPAC: Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=12, Completed, Sponsor: Baki Topal
N=15 --> 2 | Trial completion date: Oct 2026 --> Aug 2024 | Recruiting --> Terminated; PI Request Active, not recruiting --> Completed
- | Ocrevus (ocrelizumab) / Roche
Journal, Real-world evidence, Real-world: Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments. (Pubmed Central) - Sep 20, 2024
P3
To compare the treatment effect of OCR vs six DMTs' (IFN ?-1a, glatiramer acetate, fingolimod, dimethyl fumarate, teriflunomide, natalizumab) treatment pathways used in clinical practice by combining clinical trial and real-world data...These analyses suggest that high-efficacy DMTs and high treatment persistence are critical to achieve greatest clinical benefit in RMS. OPERA I (NCT01247324), OPERA II (NCT01412333).
- || Nplate (romiplostim) / Amgen, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Review, Journal: Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review. (Pubmed Central) - Sep 20, 2024
However, eltrombopag remains the most extensively studied agent. TpoR agonists had promising effects in the treatment of post-HCT thrombocytopenia with a good safety profile so far, highlighting the potential benefit of their use.
- | OM-RCA-01 / OncoMax
Preclinical, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models. (Pubmed Central) - Sep 20, 2024
TpoR agonists had promising effects in the treatment of post-HCT thrombocytopenia with a good safety profile so far, highlighting the potential benefit of their use. In
- | Rituxan (rituximab) / Roche
Journal, CAR T-Cell Therapy: Case report: Bridging radiation therapy before chimeric antigen receptor T-cell therapy induces sustained remission in patients with relapsed/refractory double-expressor diffuse large B-cell lymphoma with localized compressive symptoms. (Pubmed Central) - Sep 20, 2024
In addition, the patients did not experience serious adverse reactions related to radiotherapy as well as CAR-T cell therapy. In this article, we describe a patient with double-expressor diffuse large B-cell lymphoma with localized compression symptoms after second-line treatment failure who benefited from CAR-T combined with focal bridging radiotherapy.
- | Tecentriq (atezolizumab) / Roche
Journal: Linear immunoglobulin A bullous dermatosis induced by atezolizumab. (Pubmed Central) - Sep 20, 2024
Atezolizumab is a monoclonal antibody that targets programmed cell death ligand-1 and has been used to treat multiple cancers. Here, we report a case of drug induced LABD following the administration of Atezolizumab.
- || vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD)
Trial completion date, Monotherapy, Metastases: Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) (clinicaltrials.gov) - Sep 20, 2024
P2, N=255, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Here, we report a case of drug induced LABD following the administration of Atezolizumab. Trial completion date: Aug 2027 --> Oct 2024
- ||| volrustomig (MEDI5752) / AstraZeneca
Enrollment open, Combination therapy, Monotherapy, Metastases: eVOLVE-02: Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - Sep 20, 2024
P2, N=60, Recruiting, Sponsor: AstraZeneca
Trial completion date: Aug 2027 --> Oct 2024 Not yet recruiting --> Recruiting
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment change, Combination therapy, Monotherapy, Metastases: SKB264-II-04: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Sep 20, 2024
P2, N=498, Recruiting, Sponsor: Klus Pharma Inc.
Not yet recruiting --> Recruiting N=278 --> 498
- ||| VET3-TGI / KaliVir
Enrollment open, Combination therapy, Metastases: STEALTH-001: A Study of VET3-TGI in Patients With Solid Tumors (clinicaltrials.gov) - Sep 20, 2024
P1, N=60, Recruiting, Sponsor: KaliVir Immunotherapeutics
N=278 --> 498 Not yet recruiting --> Recruiting
- | Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date, Trial primary completion date, Combination therapy: Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides (clinicaltrials.gov) - Sep 20, 2024
P1, N=10, Recruiting, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting Trial completion date: Jun 2025 --> Jul 2026 | Trial primary completion date: Dec 2024 --> Apr 2026
- | Tyvyt (sintilimab) / Eli Lilly, Fruzaqla (fruquintinib) / Takeda
Enrollment closed, Trial primary completion date, Metastases: Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Sep 20, 2024
P2, N=29, Active, not recruiting, Sponsor: Wuhan Union Hospital, China
Trial completion date: Jun 2025 --> Jul 2026 | Trial primary completion date: Dec 2024 --> Apr 2026 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Dec 2024
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Possible thoracic metastasis from squamous cell carcinoma of the external auditory canal: A case report. (Pubmed Central) - Sep 20, 2024
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Dec 2024 Histologically, atypical keratotic cells with the same morphology as external auditory canal SCC proliferated without the figure of carcinoma in
- || Imfinzi (durvalumab) / AstraZeneca
Review, Journal, PD(L)-1 Biomarker, IO biomarker: An evaluation of durvalumab across the spectrum of urothelial carcinoma. (Pubmed Central) - Sep 20, 2024
As the complexity of UC management increases, future efforts should be directed at identifying better predictive biomarkers and selecting rational synergistic combinations from the novel treatments available. This will allow the addressing of existing gaps, facilitate the exploitation of new techniques of treatment delivery and ultimately deliver more personalized and efficacious care to the individual patient.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Journal, Metastases: Neoadjuvant treatment by toripalimab combined with chemotherapy for advanced poorly differentiated tonsillar squamous cell carcinoma: a case report (Pubmed Central) - Sep 20, 2024
This will allow the addressing of existing gaps, facilitate the exploitation of new techniques of treatment delivery and ultimately deliver more personalized and efficacious care to the individual patient. No abstract available
- | botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
Trial initiation date: BBOpCo: Botensilimab and Balstilimab Optimization in Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=15, Not yet recruiting, Sponsor: Nicholas DeVito, MD
No abstract available Initiation date: Jul 2024 --> Oct 2024
- | Onureg (azacitidine oral) / BMS, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion date, Trial primary completion date: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (clinicaltrials.gov) - Sep 20, 2024
P1, N=8, Active, not recruiting, Sponsor: Joseph Tuscano
Initiation date: Jul 2024 --> Oct 2024 Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Apr 2024 --> Dec 2024
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date, Combination therapy: Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) (clinicaltrials.gov) - Sep 20, 2024
P2, N=52, Active, not recruiting, Sponsor: Yu jiren
Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Apr 2024 --> Dec 2024 Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Sep 2023 --> Dec 2023
- || livmoniplimab (ABBV-151) / AbbVie, budigalimab (ABBV-181) / AbbVie
Enrollment closed, Adverse events, Combination therapy, Checkpoint inhibition, Metastases: LIVIGNO-1: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Sep 20, 2024
P2, N=130, Active, not recruiting, Sponsor: AbbVie
Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Sep 2023 --> Dec 2023 Recruiting --> Active, not recruiting
- | Tyvyt (sintilimab) / Eli Lilly
Enrollment closed, Trial completion date, Combination therapy: OC-001: Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 20, 2024
P2, N=51, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Jan 2027
- | Opdivo (nivolumab) / BMS
Biomarker, Journal, BRCA Biomarker, PD(L)-1 Biomarker, Circulating tumor DNA, Metastases: Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. (Pubmed Central) - Sep 20, 2024
ctDNA profiling may provide a benefit for prediction of survival and progression of HCC patients treated with nivolumab. Future studies are needed for confirmation.
- || Review, Journal: B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease. (Pubmed Central) - Sep 20, 2024
B-cell depletion therapies can be safe and effective in pediatric patients. Anticipation and mitigation of common adverse effects through primary prevention strategies, close monitoring, and appropriate symptomatic management can improve safety and tolerability.
- | Rituxan (rituximab) / Roche
Reimbursement, Retrospective data, US reimbursement, Journal, HEOR, Medicare: Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: A retrospective claims analysis (2015-2020). (Pubmed Central) - Sep 20, 2024
Anticipation and mitigation of common adverse effects through primary prevention strategies, close monitoring, and appropriate symptomatic management can improve safety and tolerability. The most common therapy was R-CHOP (70.9%) for 1?L and bendamustine?
- || Venclexta (venetoclax) / Roche, AbbVie, Jaypirca (pirtobrutinib) / Eli Lilly, Breyanzi (lisocabtagene maraleucel) / BMS
Biomarker, Review, Journal, IO biomarker: Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia. (Pubmed Central) - Sep 20, 2024
Testing for prognostic biomarkers will remain relevant to identify patients who may have increased benefit from novel therapeutic strategies, such as combination therapies and novel agents. Patients with high-risk disease should be encouraged to participate in clinical trials.
- | Tyvyt (sintilimab) / Eli Lilly
Journal, PD(L)-1 Biomarker, IO biomarker: Mechanism of tumor-associated macrophages with PD-1 monoclonal antibodies affecting vascular generation in cervical cancer via the PD-1/IRE1?/SHP2/HIF1? signaling pathway. (Pubmed Central) - Sep 20, 2024
This study discovered that PD-1 monoclonal antibodies in tumor-associated macrophages inhibit vascular generation inside cervical cancer by affecting the PD-1/IRE1?/SHP2/HIF1? signaling pathway, providing a new therapeutic target for the treatment of cervical cancer.
- | Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Journal: Pathological landscape of tumor flare reaction to epcoritamab treatment. (Pubmed Central) - Sep 20, 2024
signaling pathway, providing a new therapeutic target for the treatment of cervical cancer. This was identified as TFR, and was managed with a three-day course of intravenous dexamethasone at 12
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Enspryng (satralizumab) / Roche, Rituxan (rituximab) / Roche
Review, Journal: The pharmacological management of myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD): an update of the literature. (Pubmed Central) - Sep 20, 2024
Maintenance therapies include mycophenolate mofetil, azathioprine, IVIG, oral corticosteroids, rituximab, and interleukin-6 receptor (IL6-R) antagonists...Larger prospective studies with longer follow-ups are needed to confirm whether the blockage of the IL6-R is an effective and safe option. Since there is no evidence of major safety issues related to the new available therapies, the authors believe that waiting for disease activity to consider a possible treatment change, is an unwise approach.
- | Ibrance (palbociclib) / Pfizer
Retrospective data, Journal: Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity. (Pubmed Central) - Sep 20, 2024
Since there is no evidence of major safety issues related to the new available therapies, the authors believe that waiting for disease activity to consider a possible treatment change, is an unwise approach. ABCG2_rs2231137 variant carriers had borderline higher incidence of grade 3-4 neutropenia (OR: 4.14, 95% CI: 0.99-17.37, p
- | Hetronifly (serplulimab) / Fosun Pharma
Journal, HEOR, PD(L)-1 Biomarker, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial. (Pubmed Central) - Sep 20, 2024
Presently, the probability of serplulimab plus chemotherapy being cost-effective was 14.15%. Compared with placebo plus chemotherapy, serplulimab plus chemotherapy might not be cost-effective in the first-line treatment for advanced sqNSCLC.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system. (Pubmed Central) - Sep 20, 2024
Subgroup analyses revealed that the ICERs of pembrolizumab plus chemotherapy versus chemotherapy alone were $72,762.68 and $34,813.70 in the populations with PD-L1 CPS of 1 or higher (CPS ?1) and PD-L1 CPS???10 (CPS ?10), respectively. As first-line therapy for patients with locally advanced or metastatic HER2-negative GC/GEJC in China, pembrolizumab plus chemotherapy is less cost-effective than chemotherapy alone, however, in the CPS???10 subgroup is more.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Pembrolizumab combined with Chemotherapy versus placebo combined with Chemotherapy for HER2-negative advanced gastric cancer in China:A cost-effectiveness analysis. (Pubmed Central) - Sep 20, 2024
As first-line therapy for patients with locally advanced or metastatic HER2-negative GC/GEJC in China, pembrolizumab plus chemotherapy is less cost-effective than chemotherapy alone, however, in the CPS???10 subgroup is more. Our analysis shows the robustness of these results, as they remained consistent when input parameters were varied within a?
- ||| Ocrevus (ocrelizumab) / Roche
P3 data, Retrospective data, Journal: Sex- and age-related shift of relapse phenotypes in a cohort of relapsing multiple sclerosis patients: Post hoc analysis from the OPERA phase 3 trials. (Pubmed Central) - Sep 20, 2024
We describe sex-specific relapse presentations and an influence of age only for women. Underlying causal factors warrant further investigations.
- || Retrospective data, Review, Journal, Metastases: Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves. (Pubmed Central) - Sep 20, 2024
TAS+bevacizumab emerged as the most dominant option and may be the preferred choice; with fruquintinib, regorafenib and TAS-102 monotherapy showing statistically significant but lower PFS and OS benefits. PROSPERO: CRD42022371953.
- ||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Adverse events, Real-world evidence, Real-world: A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system. (Pubmed Central) - Sep 20, 2024
Disproportionality analysis revealed that ribociclib was related to QTp/TdP...Palbociclib and abemaciclib had no correlation with QTP/TDP events...The QT interval was monitored before and after medication. Attention should be given to adjusting the drugson time.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Stivarga (regorafenib) / Bayer
Trial primary completion date, Combination therapy, Metastases: SLOT: Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=90, Recruiting, Sponsor: Fudan University
Attention should be given to adjusting the drugson time. Trial primary completion date: Apr 2024 --> Apr 2025
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: Induction Chemo+immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (clinicaltrials.gov) - Sep 20, 2024
P2, N=40, Not yet recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
Trial primary completion date: Apr 2024 --> Apr 2025 Trial completion date: Dec 2026 --> Mar 2027 | Initiation date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2026 --> Mar 2026
- |||| anzurstobart (BMS-986351) / BMS, Erbitux (cetuximab) / Eli Lilly
Trial termination, Combination therapy, Metastases: CC-95251-ST-001: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers (clinicaltrials.gov) - Sep 20, 2024
P1, N=206, Terminated, Sponsor: Celgene
Trial completion date: Dec 2026 --> Mar 2027 | Initiation date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2026 --> Mar 2026 Active, not recruiting --> Terminated; Business objectives have changed.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Trial primary completion date: Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant (clinicaltrials.gov) - Sep 20, 2024
P1, N=50, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Business objectives have changed. Trial completion date: Jul 2024 --> Jun 2028 | Trial primary completion date: Jul 2024 --> Jun 2028
- ||| WNT974 / Novartis
Trial completion: A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (clinicaltrials.gov) - Sep 20, 2024
P1, N=185, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2024 --> Jun 2028 | Trial primary completion date: Jul 2024 --> Jun 2028 Active, not recruiting --> Completed
- || Blincyto (blinatumomab) / Astellas, Amgen
Review, Journal: A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia. (Pubmed Central) - Sep 20, 2024
Can chemotherapy-free approaches, such as blinatumomab in conjunction with more potent TKIs, obviate the need for an allograft in high-risk patients?...Can salvage therapy and a subsequent allograft cure patients who relapse after not being transplanted in CR1? This manuscript reviews the latest data influencing contemporary management and discusses these controversies.
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness of Zanubrutinib Versus Bendamustine and Rituximab in Patients With Untreated Chronic Lymphocytic Leukemia. (Pubmed Central) - Sep 20, 2024
P3
This manuscript reviews the latest data influencing contemporary management and discusses these controversies. The study highlighted the importance of considering the cost-effectiveness of zanubrutinib at its current price point for patients with untreated CLL in China, emphasizing the need for further assessment and potential pricing adjustments to enhance its economic viability in clinical practice.
- | Trial primary completion date: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response (clinicaltrials.gov) - Sep 20, 2024
P3, N=400, Recruiting, Sponsor: University of Nebraska
The study highlighted the importance of considering the cost-effectiveness of zanubrutinib at its current price point for patients with untreated CLL in China, emphasizing the need for further assessment and potential pricing adjustments to enhance its economic viability in clinical practice. Trial primary completion date: Mar 2026 --> Mar 2027
- | Opdivo (nivolumab) / BMS
Trial completion, Checkpoint inhibition: Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=41, Completed, Sponsor: Fukushima Medical University
Trial primary completion date: Mar 2026 --> Mar 2027 Unknown status --> Completed
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial: An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer (clinicaltrials.gov) - Sep 20, 2024
P=N/A, N=30, Not yet recruiting, Sponsor: Liu Shu